Two categories of data

Human mushroom safety is known from two different types of sources, and they should not be conflated:

Documented harm

The most notable signal is chaga and oxalate nephropathy: three published cases from Japan and Korea, all with biopsy-confirmed oxalate crystals in renal tubules. In one case the oxalate content of the chaga powder was measured directly — 14.2 g per 100 g, which at daily intake produced a load 2–5 times the usual dietary one. The common denominator of the cases: concentrated powder, grams a day, months and years.

The second class is drug interactions: maitake and INR elevation on warfarin (the Hanselin 2010 case), cautions on reishi and anticoagulants/immunosuppressants from the MSKCC database. The full map is in our article "Mushroom supplements and medicines".

What tolerability studies show

Where safety was measured deliberately, the picture is reassuring: Phase I trials found no toxicity at working doses, and laboratory panels (liver, kidneys, blood) stayed within normal ranges. But these studies share a common limit: they are short (weeks to months) and run in specific groups — they say "at this dose, these people had no problems", not "safe always and for everyone".

The practical boundary

Documented harm converges into one formula: concentrate + large dose + long duration + vulnerable system (kidneys, anticoagulation, immunosuppression). Culinary doses of mushrooms do not fall into this formula. Grams of chaga powder daily — falls into it squarely.

Related species

Research on this topic

Delayed pancytopenia after sulphur tuft: a clinical case

A 57-year-old man ate self-collected wild mushrooms consistent with Hypholoma fasciculare and, about 10 days later — without a violent onset — developed pancytopenia (suppression of all blood cell lines). The diagnosis was reached by exclusion; with supportive care the blood counts fully recovered.

Muscarine is released from a harmless phosphorylated precursor upon mushroom injury

In the mycelium of Clitocybe rivulosa, 4′-phosphomuscarine — a phosphorylated precursor with almost no affinity for the M3 muscarinic receptor — was identified as the major natural product. Upon cellular injury (chewing, digestion) it is dephosphorylated into lethal muscarine: the mushroom stores a 'safe' form and pulls the trigger at the moment of being eaten.

Amatoxins in the genus Lepiota: a chemotaxonomic analysis of 16 species

Amatoxins cause ~95% of fatal mushroom poisonings — and 'all Lepiota' are traditionally suspected. Phytochemistry 2022 was the first broad test of 16 species: toxins were found only in a monophyletic clade (subincarnata, brunneoincarnata, elaiophylla) — 12 species are clean. So 'lepiota = amatoxin' is itself a simplification.

Nephrotoxic mushroom poisoning: global epidemiology, clinical manifestations, and management

Diaz's 2021 review systematises nephrotoxic mushroom poisonings: while amatoxins hit the liver, orellanine webcaps and newer species (Amanita smithiana, A. proxima) attack the kidneys — acute renal failure can develop within days without signs of hepatitis. A toxidromic approach by onset of renal failure allows earlier diagnosis; hemodialysis is often indicated, kidney transplantation is the fallback.

Hydrazinic toxins of morels and 'false morels': why verpa is considered inedible

The Lagrange–Vernoux review on hydrazinic toxins: Gyromitra esculenta's disputed 'edibility' is explained by individual susceptibility; the authors suggest Verpa bohemica is likewise inedible. A transient cerebellar syndrome from heavy true-morel meals and a GI 'haemolytic' syndrome from raw or undercooked morels are described.

Cordyceps militaris in adults with mild liver dysfunction: extract efficacy and safety — an RCT

A Korean RCT in people with mild liver dysfunction (ALT 1.5–3× above normal): Cordyceps militaris extract 1.5 g/day vs. placebo with a full lab panel, liver CT and symptom scales. The preparation was tolerated safely — neither hematology nor biochemistry showed alarming shifts; the authors state protection against fatty-disease progression as a possibility, not a proven fact.

Chaga and oxalate nephropathy: documented cases of kidney injury

The best-documented harm from a "medicinal" mushroom: three published cases of oxalate nephropathy during regular chaga powder intake. Measured oxalate content in chaga — 14.2 g/100 g, exceeding ordinary dietary load 2–5×; outcomes range from reversible acute kidney injury to end-stage renal disease. A case-report format card — the canonical data type for safety.

Mercury in the gypsy mushroom: Cortinarius caperatus as an efficient accumulator

A study of mercury in 20 populations of C. caperatus: median cap concentration 0.81–2.4 mg/kg dry weight, bioconcentration factor 18–120 — even in clean forests the mushroom accumulates Hg above background. The authors' conclusion: occasional consumption is safe, but frequent season-long picking is not.

Trametes versicolor in women after breast-cancer treatment: phase I, dose escalation to 9 g/day

The classic phase I 'how much can you take': women after chemo- and radiotherapy for breast cancer took turkey tail at 3, 6 or 9 g/day for six weeks. Of nine adverse events, seven were mild, one moderate, one severe; the preparation was judged tolerable up to 9 g/day. Incidental immune shifts were trends: lymphocyte rises at 6–9 g and NK-activity gains at 6 g/day.

Maitake and warfarin: a documented INR increase with combined use

A case report from Annals of Pharmacotherapy: a patient on a stable warfarin dose developed a rise in INR (a coagulation measure) after adding maitake extract. After the extract was stopped, INR returned to target. A single documented signal — but a clinically important one: anyone on anticoagulants should monitor INR when taking maitake.

The 14 mushroom poisoning syndromes: global epidemiology and syndromic classification (review of 28,018 cases)

A descriptive review of world literature 1951–2004 collecting 28,018 confirmed mushroom poisonings. Diaz proposed an expanded syndromic classification — 14 syndromes grouped by onset time (early <6 h, late 6–24 h, delayed ≥1 day) and target organ — and formally described four new ones: accelerated nephrotoxicity (A. proxima, A. smithiana), rhabdomyolysis (T. equestre, R. subnigricans), erythromelalgia (Clitocybe spp.) and delayed neurotoxicity (Hapalopilus rutilans).

Phallotoxins outside the genus Amanita: Conocybe lactea and the taxonomy of amatoxins

Part of a larger mapping of amatoxins/phallotoxins: in Conocybe lactea no amatoxins were found — but phallotoxins were, the first detection outside the genus Amanita (in small amounts). Meanwhile C. filaris (=Pholiotina rugosa) is confirmed as a true amatoxin bearer. Both toxins and species refuse to fit the 'genus = toxin' frame.

Treatment of amatoxin poisoning: a 20-year retrospective analysis of 2,108 hospitalisations

The largest contemporary review of amatoxin-poisoning treatment: 2,108 hospitalised patients from North American and European literature over ~20 years. Penicillin G was used most often but showed little efficacy; thioctic acid and steroids showed none. Silybin (alone or in combination) and N-acetylcysteine as monotherapy were the only regimens statistically associated with survival — the analysis laid the foundation of the modern silibinin + NAC + supportive-care protocol.